Diabetes awareness survey reveals alarming figures across the Middle East and Northern Africa regions

Novo NordiskIn the lead up to World Diabetes Day 2010 on 14 November Novo Nordisk and Ipsos Emirates Health conducted a survey in ten countries of the Middle East and Northern Africa (MENA) region: Algeria, Egypt, Iran, Iraq, Jordan, Lebanon, Morocco, Kingdom of Saudi Arabia (KSA), Tunisia and the United Arab Emirates (UAE).

The survey, which was carried out in October this year, assesses the level of awareness among the general population when it comes to causes, risks and complications of diabetes. It also looks into respondents' risk of developing diabetes. With over 3,000 interviews, the respondents were representative of the demographic and socio-economic profile in each country.

The survey shows that 41% of respondents are at risk of developing diabetes. Despite a high awareness level of the scale of the disease, only one in two respondents consider diabetes to be a severe or a very severe disease. Myths about diabetes also remain very common:

  • 31% of Algerian respondents believe that diabetes is contagious
  • Stress was ranked as a leading cause of diabetes across the region (39%)
  • Half of respondents (52%) declared that stroke cannot be caused by diabetes

"The results of the MENA diabetes awareness survey are striking. The need to further educate the general public about the risk factors, complications and the severity of the condition is very clear. We hope that the initiative will inspire authorities to tackle this issue. We believe that early detection of diabetes, prevention and education can make a real difference," said Lise Kingo, executive vice president and chief of staffs at Novo Nordisk.

Diabetes is sweeping the MENA region affecting an estimated 26.6 million people today, creating overwhelming demands on the region's healthcare systems and huge financial burdens on its governments. As alarming as this picture is, the number of people with diabetes is expected to double to 51.7 million people by 2030.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Study links widely-used drug azathioprine to skin …

A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...